Premenstrual exacerbation (PME) of depression has been found to occur in roughly two-thirds of women with depressive disorders.
The researchers found that ever and past OC users had a reduced risk of anticitrullinated protein antibodies (ACPA)-positive RA compared with never users.
The concomitant use of HCV drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir is contraindicated due to the potential for liver enzyme elevations.
Delayed-release DMF exerts anti-inflammatory and neuroprotective properties for the treatment of relapsing multiple sclerosis, a disease that often develops in women between the ages of 20 and 40.
The FDA's approval of the supplemental New Drug Application (sNDA) was based on efficacy and safety data from the ongoing Phase 3 ACCESS IUS trial.
CDC researchers used birth records for nearly 100% of the births in the United States in 2016. The teen birth rate was 20.3 births per 1,000 female teens in 2016, compared to 41.5 births per 1,000 in 2007, according to the report.
In the NDA resubmission, the Company included safety and efficacy data from the Phase 3 trial SECURE, the manufacturing information, and a summary response to the CRL.
A review of recent data showed that insemination with sperm from an HIV-negative donor is the safest option for a discordant couple where the woman does not have HIV but the man is HIV-positive.
While IUD displacement has been discussed in the literature, the authors could not find a similar case which showed a displaced IUD reaching the diaphragm and causing chest pain.
The product is available in blister cards containing 28 tablets (24 active tablets containing 1mg of NA and 20mcg of EE and 4 non-hormonal placebo pills containing 75mg of Fe).
Researchers stated that there is a need for improved contraceptive access for teens, as proven by the increase in use of hormonal emergency contraceptives after the FDA approved the OTC availability under Plan B in 2012.
Even though Zika virus was found to linger for 3 months in semen, scientists say recommendations urging abstinence, condoms for 6 months after infection should still be followed.
In a study of female patients with epilepsy, retrospective data found that unintended pregnancy was common and varied by contraceptive type and antiepileptic drug (AED) stratification. Full findings are published in Neurology.
A short interpregnancy interval after termination of pregnancy is associated with increased risk of preterm birth in subsequent birth, according to a study published in the February issue of Obstetrics & Gynecology.
Allergan and Medicines360 announced that the Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Liletta (levonorgestrel-releasing intrauterine system).
Data from a large, 1-year postmarketing safety study conducted in Europe found that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation.
In a study published in Diabetes Care, researchers reported that the absolute risk of thromboembolism among women with type 1 or type 2 diabetes using hormonal contraceptives was low.
For women with diabetes who are using hormonal contraception, the absolute risk of thromboembolism is low, with the lowest rates seen with use of intrauterine and subdermal contraceptives, according to a study published online in Diabetes Care.
The Centers for Disease Control and Prevention (CDC) issued the final report on the Winnable Battles program which highlights public health priorities with large-scale impact on health and strategies that may help to address them.
Allergan announced the availability of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, the first oral contraceptive in a softgel capsule for the prevention of pregnancy.
For patients undergoing intrauterine device (IUD) insertion, oral naproxen sodium does not reduce pain on insertion, but does reduce pain after insertion
A contraceptive injection for men shows some promise, but researchers are still struggling to improve its effectiveness and deal with severe side effects caused by the injections, according to a study published online in the Journal of Clinical Endocrinology & Metabolism.
A new study published online in the journal Contraception examines whether the risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) is increased in women using non-oral combined hormonal contraceptives compared to women using combined oral contraceptives (COC).